Egetis: Receives Promising Innovative Medicine designation in the UK - Redeye

Redeye endorses today’s news that Egetis has received a “Promising Innovative Medicine (PIM) designation” in the UK, which is a first step towards its “early access to medicines scheme". We view this as a slight regulatory derisking in the UK, and consider access to the early access scheme as a promising stepping stone into the UK market.

Länk till analysen i sin helhet: https://www.redeye.se/research/1014090/egetis-receives-promising-innovative-medicine-designation-in-the-uk?utm_source=finwire&utm_medium=RSS